Yamashita Akiho, Kaku Masayuki, Ideguchi Takuya, Nishida Shuhei, Kinoshita Hiroyuki, Nishikawa Takeshi
Department of Nutrition, NHO Kumamoto Medical Center, Kumamoto 860-0008, Japan.
Department of International Medical Cooperation, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Endocr J. 2025 May 7;72(5):509-524. doi: 10.1507/endocrj.EJ24-0486. Epub 2025 Feb 5.
In Japan, the guidelines for gestational weight gain (GWG) were revised in 2021. Under the new guidelines, pregnant women are recommended to increase their GWG. The aim of this study was to compare the incidence of adverse pregnancy outcomes (APOs), large for gestational age (LGA), and postpartum glucose tolerance in gestational diabetes mellitus (GDM) patients before and after the revised GWG standards. This retrospective cohort study enrolled 1,021 GDM patients who underwent prenatal glycemic control and a postpartum 75-g oral glucose tolerance test. The endpoint was the incidence of APOs, LGA, and postpartum impaired glucose tolerance (IGT) and diabetes mellitus (DM). There was no significant difference in the incidence of APOs and postpartum IGT and DM in GDM patients before and after the revised GWG standards. On the other hand, when the new GWG standards were applied to GDM patients, the incidence of LGA increased (adjusted odds ratio [aOR]; 1.764, 95% confidence interval [CI]; 1.180-2.637). In particular, when classified by pre-pregnancy body mass index, the incidence of LGA increased in the obese group (aOR; 5.944, 95% CI; 1.847-19.129). Future prospective cohort studies are needed to verify the efficacy and safety of appropriate GWG in Japanese GDM patients.
在日本,2021年修订了妊娠期体重增加(GWG)指南。根据新指南,建议孕妇增加妊娠期体重。本研究的目的是比较修订后的GWG标准前后,妊娠期糖尿病(GDM)患者不良妊娠结局(APO)、大于胎龄儿(LGA)和产后糖耐量的发生率。这项回顾性队列研究纳入了1021例接受产前血糖控制和产后75克口服葡萄糖耐量试验的GDM患者。终点指标为APO、LGA以及产后糖耐量受损(IGT)和糖尿病(DM)的发生率。修订后的GWG标准前后,GDM患者的APO、产后IGT和DM发生率无显著差异。另一方面,将新的GWG标准应用于GDM患者时,LGA的发生率增加(调整优势比[aOR];1.764,95%置信区间[CI];1.180 - 2.637)。特别是按孕前体重指数分类时,肥胖组LGA的发生率增加(aOR;5.944,95% CI;1.847 - 19.129)。未来需要进行前瞻性队列研究,以验证日本GDM患者适当GWG的有效性和安全性。